PD05-05 THE REAL-LIFE PRACTICE OF INTRAVESICAL BOTULINUM TOXIN A INJECTION FOR INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME - SATISFACTION RATE AND PREDICTIVE FACTORS

Abstract

You have accessJournal of UrologyCME1 Apr 2023PD05-05 THE REAL-LIFE PRACTICE OF INTRAVESICAL BOTULINUM TOXIN A INJECTION FOR INTERSTITIAL CYSTITIS/BLADDER PAIN SYNDROME - SATISFACTION RATE AND PREDICTIVE FACTORS Wei-Hsin Chen, Wan-Ru Yu, Jia-Fong Jhang, Yuan-Hong Jiang, and Hann-Chorng Kuo Wei-Hsin ChenWei-Hsin Chen More articles by this author , Wan-Ru YuWan-Ru Yu More articles by this author , Jia-Fong JhangJia-Fong Jhang More articles by this author , Yuan-Hong JiangYuan-Hong Jiang More articles by this author , and Hann-Chorng KuoHann-Chorng Kuo More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003229.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Botulinum toxin A (BoNT-A) has been demonstrated to have anti-inflammatory and antinociceptive effects on bladder sensory disorders and has been shown effective in reducing bladder oversensitivity and increasing functional bladder capacity, however, the real-world treatment outcome on interstitial cystitis/bladder pain syndrome (IC/BPS) is still lacking. This study investigated the real-life practice of intravesical BoNT-A injection for patients with IC/BPS. METHODS: This retrospective study included IC/BPS patients treated with 100U BoNT-A intravesical injection in the past twenty years. The treatment outcomes were assessed by the global response assessment (GRA) at 6 months post treatment. The treatment outcome was assessed by classification according to the GRA, clinical symptoms, urodynamic parameters, cystoscopic characteristics, and urine biomarkers, and the predictive factors for a satisfactory outcome were investigated. RESULTS: Of a total of 220 patients (180 females, 40 males) enrolled in this study who received the BoNT-A injection, only 87 (40%) of patients had significantly satisfactory treatment outcomes; the satisfactory group has a significantly larger voided-volume, a lower urinary inflammatory protein MCP-1, and oxidative stress biomarker 8-isoprostane than the unsatisfactory group (Table 1). The IC severity and detrusor pressure are predictive factors to affect treatment outcomes under BoNT-A injection (Figure 1). CONCLUSIONS: IC/BPS patients with less inflammation in the bladder have a satisfactory outcome to intravesical BoNT-A injection. Patients with higher grade of bladder inflammation might need more intravesical BoNT-A injections to achieve a satisfactory outcome. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e150 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Wei-Hsin Chen More articles by this author Wan-Ru Yu More articles by this author Jia-Fong Jhang More articles by this author Yuan-Hong Jiang More articles by this author Hann-Chorng Kuo More articles by this author Expand All Advertisement PDF downloadLoading ...